Bristol-Myers Squibb Co. (BMY) | Common-Size Statement of Financial Position, Liabilities and Stockholders' Equity
See also
- Johnson & Johnson (JNJ), Common-Size Liabilities and Stockholders' Equity
- Pfizer Inc. (PFE), Common-Size Liabilities and Stockholders' Equity
- Novartis AG (NVS), Common-Size Liabilities and Stockholders' Equity
- Merck & Co. Inc. (MRK), Common-Size Liabilities and Stockholders' Equity
- GlaxoSmithKline PLC (GSK), Common-Size Liabilities and Stockholders' Equity
- Abbott Laboratories (ABT), Common-Size Liabilities and Stockholders' Equity
- Sanofi (SNY), Common-Size Liabilities and Stockholders' Equity
- Novo Nordisk A/S (NVO), Common-Size Liabilities and Stockholders' Equity
- UnitedHealth Group Inc. (UNH), Common-Size Liabilities and Stockholders' Equity
- AstraZeneca PLC (AZN), Common-Size Liabilities and Stockholders' Equity
- Eli Lilly & Co. (LLY), Common-Size Liabilities and Stockholders' Equity
- Medtronic Inc. (MDT), Common-Size Liabilities and Stockholders' Equity
- Baxter International Inc. (BAX), Common-Size Liabilities and Stockholders' Equity
ˇ Show More
You have visited 10 password protected pages for free. Others contain data covered by 
.
Sign Up Now to get full access to whole website and cut out all advertisements.
Bristol-Myers Squibb Co., Common-Size Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | ||
|---|---|---|---|---|---|---|
 |
Short-term borrowings | |
|
|
|
|
|
Accounts payable | |
|
|
|
|
|
Employee compensation and benefits | |
|
|
|
|
|
Royalties | |
|
|
|
|
|
Accrued research and development | |
|
|
|
|
|
Restructuring, current | |
|
|
|
|
|
Pension and postretirement benefits | |
|
|
|
|
|
Accrued litigation | |
|
|
|
|
|
Other | |
|
|
|
|
|
Accrued expenses | % |
% |
% |
% |
% |
|
Deferred income | |
|
|
|
|
|
Accrued rebates and returns | |
|
|
|
|
|
U.S. and foreign income taxes payable | |
|
|
|
|
|
Dividends payable | |
|
|
|
|
|
Liabilities related to assets held for sale | |
|
|
|
|
|
Current liabilities | % |
% |
% |
% |
% |
|
Pension, postretirement and postemployment liabilities | |
|
|
|
|
|
Deferred income | |
|
|
|
|
|
U.S. and foreign income taxes payable | |
|
|
|
|
|
Other liabilities | |
|
|
|
|
|
Long-term debt | |
|
|
|
|
|
Non-current liabilities | % |
% |
% |
% |
% |
|
Total liabilities | % |
% |
% |
% |
% |
|
Preferred stock, $2 convertible series, par value $1 per share | |
|
|
|
|
|
Common stock, par value of $0.10 per share | |
|
|
|
|
|
Capital in excess of par value of stock | |
|
|
|
|
|
Accumulated other comprehensive loss | |
|
|
|
|
|
Retained earnings | |
|
|
|
|
|
Cost of treasury stock | |
|
|
|
|
|
Bristol-Myers Squibb Company shareholders’ equity | % |
% |
% |
% |
% |
|
Noncontrolling interest | |
|
|
|
|
|
Total equity | % |
% |
% |
% |
% |
|
Total liabilities and equity | % |
% |
% |
% |
% |
Stock Analysis on Net (www.stock-analysis-on.net)
Copyright © 2012 EBIT Financial Analyses Center